Interestingly, in group 2, which comprised seven patients with advanced HGNECC who started immunotherapy as the first-line treatment, minimal benefits were observed in terms of PFS and OS, although they did not reach statistical significance.
← all excerpts
Efficacy of PD-1/PD-L1 blockade immunotherapy in recurrent/metastatic high-grade neuroendocrine carcinoma of the cervix: A retrospective study.
1
—
—